
Kardigan, Inc.
KARDPro trackingKardigan, Inc. · Nasdaq · Research source · 424B4 · 2026-06-18 · Latest filing · 10-Q · 2026-11-12 SEC ↗
IPO research
The final prospectus dated June 17, 2026 priced 25,000,000 primary shares at $16, with a 30-day option for 3,750,000 more. It states Nasdaq approval under KARD and expected delivery around June 22, 2026; those historical statements do not independently confirm current trading or settlement.
Full source-backed summary
Kardigan is a well-funded but pre-revenue cardiovascular biotech advancing three mid-to-late-stage candidates in parallel. The $400 million IPO extends its stated runway into 2028 and funds defined clinical milestones, but the investment remains highly dependent on unapproved assets, costly trials, licensed rights and future financing. The $1.43 billion offer-price equity value and 55.4% tangible-book dilution price in substantial execution expectations.
The final prospectus dated June 17, 2026 priced 25,000,000 primary shares at $16, with a 30-day option for 3,750,000 more. It states Nasdaq approval under KARD and expected delivery around June 22, 2026; those historical statements do not independently confirm current trading or settlement.
- Business and development direction
Kardigan, Inc.
Current business Future development
Key risks
Risk 1
No product is approved and no revenue has been generated; commercial revenue is not expected for at least several years, if ever.
Risk 2
Quarterly net loss more than tripled year over year to $56.1 million as three programs advanced in parallel.
Risk 3
The Prolaio approach to trial design is novel and may fail to deliver anticipated efficiency or regulatory acceptance.
Sources and calculation notes
Read this report’s SEC filing ↗
| View | Source basis |
|---|---|
| Offering quality | Some sourced inputs are available; a compatible set is needed for this view. Open filing ↗ |
| # | Institution | Underwriting allocation | Ratio · calculated | Shares |
|---|---|---|---|---|
| 1 | J.P. Morgan Securities LLC | 35.75% | 8,937,500 shares | |
| 2 | Jefferies LLC | 25.75% | 6,437,500 shares | |
| 3 | Leerink Partners LLC | 20.75% | 5,187,500 shares | |
| 4 | TD Securities (USA) LLC | 17.75% | 4,437,500 shares |
Ratio = institution commitment ÷ complete source-table total (25,000,000 shares) × 100.
Underwriting terms
| Measure | Reported value | Unit |
|---|---|---|
| Underwriting discount per share | $1.12 | $ / share |
| Total underwriting discount | $28,000,000 | $ |
Source and calculation
Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.
Base prospectus offering; cover per-share and total columns
SEC table 1 row 7; source 1998:5701; SHA256 3d0c4013ddccd0a4423e43e1920c3046502562a708a11084e7672996a02f443e ↗Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.
Base prospectus offering; cover per-share and total columns
SEC table 1 row 7; source 1998:5701; SHA256 3d0c4013ddccd0a4423e43e1920c3046502562a708a11084e7672996a02f443e ↗IPO CAPITAL QUALITY
Basis and evidence
424B4 · 2026-06-18
The final prospectus dated June 17, 2026 priced 25,000,000 primary shares at $16, with a 30-day option for 3,750,000 more. It states Nasdaq approval under KARD and expected delivery around June 22, 2026; those historical statements do not independently confirm current trading or settlement.
Offering structure
| Measure | Reported value | Unit |
|---|---|---|
| Offering price | $16 | $ / share |
| Gross offering amount | $400,000,000 | $ |
Source and calculation
Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.
Base prospectus offering; cover per-share and total columns
SEC table 1 row 5; source 1998:5701; SHA256 3d0c4013ddccd0a4423e43e1920c3046502562a708a11084e7672996a02f443e ↗Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.
Base prospectus offering; cover per-share and total columns
SEC table 1 row 5; source 1998:5701; SHA256 3d0c4013ddccd0a4423e43e1920c3046502562a708a11084e7672996a02f443e ↗Proceeds and intended uses
| Measure | Reported value | Unit |
|---|---|---|
| Issuer proceeds before expenses | $372,000,000 | $ |
Source and calculation
Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.
Base prospectus offering; cover per-share and total columns
SEC table 1 row 9; source 1998:5701; SHA256 3d0c4013ddccd0a4423e43e1920c3046502562a708a11084e7672996a02f443e ↗Dilution and valuation
| Calculation | Shares | Value | Reference |
|---|---|---|---|
| Base post-offer valuation | ≈ 89.3391M | ≈ $1.4294B | |
| Post-offer shares — base/no option | 89,339,121 | — | |
| Post-offer shares — full option | 93,089,121 | — | |
| Offering price | — | $16 | |
| Gross offering amount | — | $400,000,000 |
Basis and evidence ↗
Prospectus share summary; Common stock to be outstanding immediately after this offering; 89,339,121 shares (or 93,089,121 shares if the underwriters exercise their option to purchase additional shares of common stock in full). We will have two series of common stock authorized immediately following this offering: voting common stock and non-voting common stock. We are offering voting common stock in this offering and unless otherwise noted, all references in this prospectus to our “common stock” refer to our voting common stock. The non-voting common stock will not be listed for trading on any securities exchange. Immediately after consummation of this offering, no shares of non-voting stock will be outstanding, and we have no present intention to issue any shares of non-voting common stock.; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value
Figures retain their stated source scenario and conditions.
Prospectus share summary; Common stock to be outstanding immediately after this offering; 89,339,121 shares (or 93,089,121 shares if the underwriters exercise their option to purchase additional shares of common stock in full). We will have two series of common stock authorized immediately following this offering: voting common stock and non-voting common stock. We are offering voting common stock in this offering and unless otherwise noted, all references in this prospectus to our “common stock” refer to our voting common stock. The non-voting common stock will not be listed for trading on any securities exchange. Immediately after consummation of this offering, no shares of non-voting stock will be outstanding, and we have no present intention to issue any shares of non-voting common stock.; selected security: shares; selected scenario: full option; no inferred sum, conversion or equity value
Figures retain their stated source scenario and conditions.
Base prospectus offering; cover per-share and total columns
Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.
completion-of-this-offering
Base prospectus offering; cover per-share and total columns
Prospectus share summary; Common stock to be outstanding immediately after this offering; 89,339,121 shares (or 93,089,121 shares if the underwriters exercise their option to purchase additional shares of common stock in full). We will have two series of common stock authorized immediately following this offering: voting common stock and non-voting common stock. We are offering voting common stock in this offering and unless otherwise noted, all references in this prospectus to our “common stock” refer to our voting common stock. The non-voting common stock will not be listed for trading on any securities exchange. Immediately after consummation of this offering, no shares of non-voting stock will be outstanding, and we have no present intention to issue any shares of non-voting common stock.; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value
Exact input · Offering price: $16
Exact input · Post-offer shares — base/no option: 89,339,121
Prospectus share summary; Common stock to be outstanding immediately after this offering; 89,339,121 shares (or 93,089,121 shares if the underwriters exercise their option to purchase additional shares of common stock in full). We will have two series of common stock authorized immediately following this offering: voting common stock and non-voting common stock. We are offering voting common stock in this offering and unless otherwise noted, all references in this prospectus to our “common stock” refer to our voting common stock. The non-voting common stock will not be listed for trading on any securities exchange. Immediately after consummation of this offering, no shares of non-voting stock will be outstanding, and we have no present intention to issue any shares of non-voting common stock.; selected security: shares; selected scenario: full option; no inferred sum, conversion or equity value
Exact input · Post-offer shares — full option: 93,089,121
completion-of-this-offering
Base prospectus offering; cover per-share and total columns
Prospectus share summary; Common stock to be outstanding immediately after this offering; 89,339,121 shares (or 93,089,121 shares if the underwriters exercise their option to purchase additional shares of common stock in full). We will have two series of common stock authorized immediately following this offering: voting common stock and non-voting common stock. We are offering voting common stock in this offering and unless otherwise noted, all references in this prospectus to our “common stock” refer to our voting common stock. The non-voting common stock will not be listed for trading on any securities exchange. Immediately after consummation of this offering, no shares of non-voting stock will be outstanding, and we have no present intention to issue any shares of non-voting common stock.; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value
completion-of-this-offering
Base prospectus offering; cover per-share and total columns
Prospectus share summary; Common stock to be outstanding immediately after this offering; 89,339,121 shares (or 93,089,121 shares if the underwriters exercise their option to purchase additional shares of common stock in full). We will have two series of common stock authorized immediately following this offering: voting common stock and non-voting common stock. We are offering voting common stock in this offering and unless otherwise noted, all references in this prospectus to our “common stock” refer to our voting common stock. The non-voting common stock will not be listed for trading on any securities exchange. Immediately after consummation of this offering, no shares of non-voting stock will be outstanding, and we have no present intention to issue any shares of non-voting common stock.; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value
Prospectus share summary; Common stock to be outstanding immediately after this offering; 89,339,121 shares (or 93,089,121 shares if the underwriters exercise their option to purchase additional shares of common stock in full). We will have two series of common stock authorized immediately following this offering: voting common stock and non-voting common stock. We are offering voting common stock in this offering and unless otherwise noted, all references in this prospectus to our “common stock” refer to our voting common stock. The non-voting common stock will not be listed for trading on any securities exchange. Immediately after consummation of this offering, no shares of non-voting stock will be outstanding, and we have no present intention to issue any shares of non-voting common stock.; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value
Base prospectus offering; cover per-share and total columns
Prospectus share summary; Common stock to be outstanding immediately after this offering; 89,339,121 shares (or 93,089,121 shares if the underwriters exercise their option to purchase additional shares of common stock in full). We will have two series of common stock authorized immediately following this offering: voting common stock and non-voting common stock. We are offering voting common stock in this offering and unless otherwise noted, all references in this prospectus to our “common stock” refer to our voting common stock. The non-voting common stock will not be listed for trading on any securities exchange. Immediately after consummation of this offering, no shares of non-voting stock will be outstanding, and we have no present intention to issue any shares of non-voting common stock.; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value
Exact input · Post-offer shares — base/no option: 89,339,121
Exact input · Offering price: $16
Share-count comparison
A compatible whole-issuer pre-offer share count is missing; existing-holder or offered-share allocations cannot substitute for it.
Source ↗IPO valuation scenario simulator
Offering completion · $16 × ≈ 89.3391M shares · Final
Source and calculation ↗
Reported point prices retain their security, class, currency and per-security unit; range endpoints remain separate.
Reported whole-issuer base counts retain explicit option, conversion and surrender assumptions.
Equity value is the exact product of the selected compatible per-share price and whole-issuer post-offer count.
A compatible whole-issuer pre-offer share count is missing; existing-holder or offered-share allocations cannot substitute for it.
Each reported full-option, actual, diluted or class-specific case remains independent; no class sum or cross-date substitution is inferred.
The exact selected base supports transparent hypothetical price/share changes; it is not a forecast or tradable float.
The current source URL, accession, hash, proof variants, footnotes, input IDs and executable formulas remain attached. Missing source dates and precision gaps remain explicit.
$16 × 89,339,121 = $1,429,425,936 [summary-table-49-base-1-price, summary-table-49-base-1-post]
Exact calculation · Derived whole-issuer equity value: $1,429,425,936
Sources and calculation notes
Read this report’s SEC filing ↗
| View | Source basis |
|---|---|
| Ownership across stages | Some sourced inputs are available; a compatible set is needed for this view. Open filing ↗ |
- As of
- 2026-06-18
Relationship filters
Select for details · Kardigan, Inc.
Holdings and voting rights
Holder groups may overlap; these rows are not an additive ownership partition.
| Holder / measure | Shares | Ownership | Voting rights | Reference |
|---|---|---|---|---|
| our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliatesOwnership as disclosed | — | approximately 86.0%Beneficial | — | Source statement; approximately ; source predicate: beneficially owned; primary source clause; source condition: assuming no exercise of the underwriters’ option to purchase additional shares and without giving effect to (i) the issuance of equity awards granted to certain of our employees and non-employee directors upon the pricing of this offering and (ii) ; source scope: of our voting stock and, upon the completion of this offering, that same group will hold approximately; not an additive ownership partition |
| our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliatesOwnership as disclosed | — | approximately 63.5%Beneficial | — | Source statement; approximately ; source predicate: will hold; primary source clause; source condition: assuming no exercise of the underwriters’ option to purchase additional shares and without giving effect to (i) the issuance of equity awards granted to certain of our employees and non-employee directors upon the pricing of this offering and (ii) ; source scope: of our outstanding voting stock (assuming no exercise of the underwriters’ option to purchase additional shares and without giving effect to (i) the issuance of equity awards granted to certain of ou; not an additive ownership partition |
| Entities affiliated with ARCHBeneficial shares | 14,668,075 | — | — | Number of sharesbeneficially owned |
| Entities affiliated with HRTG PartnersBeneficial shares | 14,688,074 | — | — | Number of sharesbeneficially owned |
| Entities affiliated with PerceptiveBeneficial shares | 8,200,661 | — | — | Number of sharesbeneficially owned |
| Entities affiliated with FidelityBeneficial shares | 4,473,086 | — | — | Number of sharesbeneficially owned |
| Tassos Gianakakos, Chief Executive Officer, Director, and ChairBeneficial shares | 9,806,633 | — | — | Number of sharesbeneficially owned |
| Jay Edelberg, M.D., Ph.D., Chief Medical OfficerBeneficial shares | 4,599,237 | — | — | Number of sharesbeneficially owned |
| Brianne Puglisi, Chief Financial OfficerBeneficial shares | 184,718 | — | — | Number of sharesbeneficially owned |
| Andy Pasternak, Chief Strategy OfficerBeneficial shares | 31,339 | — | — | Number of sharesbeneficially owned |
| Paul BernsBeneficial shares | 53,483 | — | — | Number of sharesbeneficially owned |
| David Meeker, M.D.Beneficial shares | 37,358 | — | — | Number of sharesbeneficially owned |
| Douglas GiordanoBeneficial shares | 53,483 | — | — | Number of sharesbeneficially owned |
| Kim PopovitsBeneficial shares | 37,358 | — | — | Number of sharesbeneficially owned |
| Entities affiliated with ARCHBeneficial ownership | — | 22.4%Beneficial | — | Percentage of sharesbeneficially owned; Beforeoffering |
| Entities affiliated with ARCHBeneficial ownership | — | 16.5%Beneficial | — | Percentage of sharesbeneficially owned; Afteroffering |
| Entities affiliated with HRTG PartnersBeneficial ownership | — | 22.4%Beneficial | — | Percentage of sharesbeneficially owned; Beforeoffering |
| Entities affiliated with HRTG PartnersBeneficial ownership | — | 16.6%Beneficial | — | Percentage of sharesbeneficially owned; Afteroffering |
| Entities affiliated with PerceptiveBeneficial ownership | — | 12.7%Beneficial | — | Percentage of sharesbeneficially owned; Beforeoffering |
| Entities affiliated with PerceptiveBeneficial ownership | — | 9.3%Beneficial | — | Percentage of sharesbeneficially owned; Afteroffering |
| Entities affiliated with FidelityBeneficial ownership | — | 6.9%Beneficial | — | Percentage of sharesbeneficially owned; Beforeoffering |
| Entities affiliated with FidelityBeneficial ownership | — | 5.1%Beneficial | — | Percentage of sharesbeneficially owned; Afteroffering |
| Tassos Gianakakos, Chief Executive Officer, Director, and ChairBeneficial ownership | — | 15.2%Beneficial | — | Percentage of sharesbeneficially owned; Beforeoffering |
| Tassos Gianakakos, Chief Executive Officer, Director, and ChairBeneficial ownership | — | 11.2%Beneficial | — | Percentage of sharesbeneficially owned; Afteroffering |
| Jay Edelberg, M.D., Ph.D., Chief Medical OfficerBeneficial ownership | — | 7.1%Beneficial | — | Percentage of sharesbeneficially owned; Beforeoffering |
| Jay Edelberg, M.D., Ph.D., Chief Medical OfficerBeneficial ownership | — | 5.2%Beneficial | — | Percentage of sharesbeneficially owned; Afteroffering |
| All executive officers and directors as a group (10 persons)Beneficial shares | 14,803,609 | — | — | Number of sharesbeneficially owned |
| All executive officers and directors as a group (10 persons)Beneficial ownership | — | 22.6%Beneficial | — | Percentage of sharesbeneficially owned; Beforeoffering |
| All executive officers and directors as a group (10 persons)Beneficial ownership | — | 16.6%Beneficial | — | Percentage of sharesbeneficially owned; Afteroffering |
| voting common stockper-share voting rights | — | — | 1 vote per shareVotes per share | Literal source per-share voting entitlement; voting common stock; subject to the express source qualifications; full source conditions retained; not a holder voting percentage, ownership amount or controller finding; Source capital-stock section applies at the stated completion/consummation stage of this offering; certificate/bylaw effectiveness conditions remain applicable |
Source and calculation ↗
Source statement; approximately ; source predicate: beneficially owned; primary source clause; source condition: assuming no exercise of the underwriters’ option to purchase additional shares and without giving effect to (i) the issuance of equity awards granted to certain of our employees and non-employee directors upon the pricing of this offering and (ii) ; source scope: of our voting stock and, upon the completion of this offering, that same group will hold approximately; not an additive ownership partition
Based on the beneficial ownership of our common stock as of June 5, 2026, prior to this offering, our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates beneficially owned approximately 86.0% of our voting stock and, upon the completion of this offering, that same group will hold approximately 63.5% of our outstanding voting stock (assuming no exercise of the underwriters’ option to purchase additional shares and without giving effect to (i) the issuance of equity awards granted to certain of our employees and non-employee directors upon the pricing of this offering and (ii) no purchases of shares by this group in this offering), in each case assuming the conversion of all outstanding shares of our redeemable convertible preferred stock into shares of our common stock. As a result, these stockholders, if acting together, will continue to have significant influence over the outcome of corporate actions requiring stockholder approval, including the election of directors, amendment of our organizational documents, any merger,
Source statement; approximately ; source predicate: will hold; primary source clause; source condition: assuming no exercise of the underwriters’ option to purchase additional shares and without giving effect to (i) the issuance of equity awards granted to certain of our employees and non-employee directors upon the pricing of this offering and (ii) ; source scope: of our outstanding voting stock (assuming no exercise of the underwriters’ option to purchase additional shares and without giving effect to (i) the issuance of equity awards granted to certain of ou; not an additive ownership partition
Based on the beneficial ownership of our common stock as of June 5, 2026, prior to this offering, our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates beneficially owned approximately 86.0% of our voting stock and, upon the completion of this offering, that same group will hold approximately 63.5% of our outstanding voting stock (assuming no exercise of the underwriters’ option to purchase additional shares and without giving effect to (i) the issuance of equity awards granted to certain of our employees and non-employee directors upon the pricing of this offering and (ii) no purchases of shares by this group in this offering), in each case assuming the conversion of all outstanding shares of our redeemable convertible preferred stock into shares of our common stock. As a result, these stockholders, if acting together, will continue to have significant influence over the outcome of corporate actions requiring stockholder approval, including the election of directors, amendment of our organizational documents, any merger,
Exact source ownership column: Number of sharesbeneficially owned; holders may overlap; not an additive partition
Raw source column: Number of sharesbeneficially owned; source holder: Entities affiliated with ARCH (1)
Exact source ownership column: Number of sharesbeneficially owned; holders may overlap; not an additive partition
Raw source column: Number of sharesbeneficially owned; source holder: Entities affiliated with HRTG Partners (2)
Exact source ownership column: Number of sharesbeneficially owned; holders may overlap; not an additive partition
Raw source column: Number of sharesbeneficially owned; source holder: Entities affiliated with Perceptive (3)
Exact source ownership column: Number of sharesbeneficially owned; holders may overlap; not an additive partition
Raw source column: Number of sharesbeneficially owned; source holder: Entities affiliated with Fidelity (4)
Exact source ownership column: Number of sharesbeneficially owned; holders may overlap; not an additive partition
Raw source column: Number of sharesbeneficially owned; source holder: Tassos Gianakakos, Chief Executive Officer, Director, and Chair (5)
Exact source ownership column: Number of sharesbeneficially owned; holders may overlap; not an additive partition
Raw source column: Number of sharesbeneficially owned; source holder: Jay Edelberg, M.D., Ph.D., Chief Medical Officer (6)
Exact source ownership column: Number of sharesbeneficially owned; holders may overlap; not an additive partition
Raw source column: Number of sharesbeneficially owned; source holder: Brianne Puglisi, Chief Financial Officer (7)
Exact source ownership column: Number of sharesbeneficially owned; holders may overlap; not an additive partition
Raw source column: Number of sharesbeneficially owned; source holder: Andy Pasternak, Chief Strategy Officer (8)
Exact source ownership column: Number of sharesbeneficially owned; holders may overlap; not an additive partition
Raw source column: Number of sharesbeneficially owned; source holder: Paul Berns (9)
Exact source ownership column: Number of sharesbeneficially owned; holders may overlap; not an additive partition
Raw source column: Number of sharesbeneficially owned; source holder: David Meeker, M.D. (10)
Exact source ownership column: Number of sharesbeneficially owned; holders may overlap; not an additive partition
Raw source column: Number of sharesbeneficially owned; source holder: Douglas Giordano (11)
Exact source ownership column: Number of sharesbeneficially owned; holders may overlap; not an additive partition
Raw source column: Number of sharesbeneficially owned; source holder: Kim Popovits (12)
Exact source ownership column: Percentage of sharesbeneficially owned; Beforeoffering; holders may overlap; not an additive partition
Raw source column: Percentage of sharesbeneficially owned; Beforeoffering; source holder: Entities affiliated with ARCH (1)
Exact source ownership column: Percentage of sharesbeneficially owned; Afteroffering; holders may overlap; not an additive partition
Raw source column: Percentage of sharesbeneficially owned; Afteroffering; source holder: Entities affiliated with ARCH (1)
Exact source ownership column: Percentage of sharesbeneficially owned; Beforeoffering; holders may overlap; not an additive partition
Raw source column: Percentage of sharesbeneficially owned; Beforeoffering; source holder: Entities affiliated with HRTG Partners (2)
Exact source ownership column: Percentage of sharesbeneficially owned; Afteroffering; holders may overlap; not an additive partition
Raw source column: Percentage of sharesbeneficially owned; Afteroffering; source holder: Entities affiliated with HRTG Partners (2)
Exact source ownership column: Percentage of sharesbeneficially owned; Beforeoffering; holders may overlap; not an additive partition
Raw source column: Percentage of sharesbeneficially owned; Beforeoffering; source holder: Entities affiliated with Perceptive (3)
Exact source ownership column: Percentage of sharesbeneficially owned; Afteroffering; holders may overlap; not an additive partition
Raw source column: Percentage of sharesbeneficially owned; Afteroffering; source holder: Entities affiliated with Perceptive (3)
Exact source ownership column: Percentage of sharesbeneficially owned; Beforeoffering; holders may overlap; not an additive partition
Raw source column: Percentage of sharesbeneficially owned; Beforeoffering; source holder: Entities affiliated with Fidelity (4)
Exact source ownership column: Percentage of sharesbeneficially owned; Afteroffering; holders may overlap; not an additive partition
Raw source column: Percentage of sharesbeneficially owned; Afteroffering; source holder: Entities affiliated with Fidelity (4)
Exact source ownership column: Percentage of sharesbeneficially owned; Beforeoffering; holders may overlap; not an additive partition
Raw source column: Percentage of sharesbeneficially owned; Beforeoffering; source holder: Tassos Gianakakos, Chief Executive Officer, Director, and Chair (5)
Exact source ownership column: Percentage of sharesbeneficially owned; Afteroffering; holders may overlap; not an additive partition
Raw source column: Percentage of sharesbeneficially owned; Afteroffering; source holder: Tassos Gianakakos, Chief Executive Officer, Director, and Chair (5)
Exact source ownership column: Percentage of sharesbeneficially owned; Beforeoffering; holders may overlap; not an additive partition
Raw source column: Percentage of sharesbeneficially owned; Beforeoffering; source holder: Jay Edelberg, M.D., Ph.D., Chief Medical Officer (6)
Exact source ownership column: Percentage of sharesbeneficially owned; Afteroffering; holders may overlap; not an additive partition
Raw source column: Percentage of sharesbeneficially owned; Afteroffering; source holder: Jay Edelberg, M.D., Ph.D., Chief Medical Officer (6)
Exact source ownership column: Number of sharesbeneficially owned; holders may overlap; not an additive partition
Raw source column: Number of sharesbeneficially owned; source holder: All executive officers and directors as a group (10 persons)
Exact source ownership column: Percentage of sharesbeneficially owned; Beforeoffering; holders may overlap; not an additive partition
Raw source column: Percentage of sharesbeneficially owned; Beforeoffering; source holder: All executive officers and directors as a group (10 persons)
Exact source ownership column: Percentage of sharesbeneficially owned; Afteroffering; holders may overlap; not an additive partition
Raw source column: Percentage of sharesbeneficially owned; Afteroffering; source holder: All executive officers and directors as a group (10 persons)
Literal source per-share voting entitlement; voting common stock; subject to the express source qualifications; full source conditions retained; not a holder voting percentage, ownership amount or controller finding; Source capital-stock section applies at the stated completion/consummation stage of this offering; certificate/bylaw effectiveness conditions remain applicable
Except as otherwise expressly provided in our amended and restated certificate of incorporation or as required by applicable law, on any matter that is submitted to a vote by our stockholders, holders of our voting common stock are entitled to one vote per share of voting common stock, and holders of our non-voting common stock are not entitled to any votes per share of non-voting common stock, including for the election of directors. In particular, under Section 242(b)(2) of the DGCL, holders of non-voting common stock are entitled to vote separately as a class on amendments to a certificate of incorporation that adversely affects the powers, preferences or special rights of that class. Holders of our voting common stock have no conversion rights, while holders of our non-voting common stock shall have the right to convert each share of our non-voting common stock into one share of voting common stock at such holder’s election, provided that as a result of such conversion, such holder, together with its affiliates and any members of a Schedule 13(d) group with such holder, would not beneficially own in excess of 9.99% of our common stock immediately prior to and following such conversion, unless otherwise as expressly provided for in our amended and restated certificate of incorporation. However, this ownership limitation may be increased or decreased to any other percentage (not to exceed 19.99%) designated by such holder of non-voting common stock upon 61 days’ notice to us. There are no mandatory conversion terms associated with the non-voting common stock. The holders of our common stock do not have any cumulative voting rights. Holders of our common stock and non-voting common stock are entitled to receive ratably any dividends declared by our board of directors out of funds legally available for Source context: The following description of our capital stock and certain provisions of our third amended and restated certificate of incorporation and amended and restated bylaws are summaries and are qualified by reference to the third amended and restated certificate of incorporation, which will become effective upon the completion of this offering, and the amended and restated bylaws, which became effective upon the effectiveness of the registration statement of which this prospectus forms a part. Copies of these documents have been filed with the SEC as exhibits to our registration statement, of which this prospectus forms a part. The descriptions of the common stock and preferred stock reflect changes to our capital structure that will be in effect on the completion of this offering.
Economic ownership
A chart needs complete, non-overlapping economic interests on one date and share basis. The disclosed holder figures remain in the table.
Share supply
Source lock-up conditions
Literal day restriction; after date of this prospectus; full conditions and exceptions remain in the source paragraph
| Measure | Reported value |
|---|---|
| WeAfter date of this prospectus · Source conditions apply | 180 days |
| our stockholders with us or lock-up agreements entered into by our directors, officers and substantially all of our stockholders with the underwriters in connection with this offering under which theyAfter date of this prospectus · Source conditions apply | 180 days |
Source and calculation
We have agreed that we will not (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, or submit to, or file with, the Securities and Exchange Commission a registration statement under the Securities Act relating to, any shares of our common stock or securities convertible into or exercisable or exchangeable for any shares of our common stock, or publicly disclose the intention to make any offer, sale, pledge, loan, disposition or filing, or (ii) enter into any swap or other arrangement that transfers all or a portion of the economic consequences associated with the ownership of any shares of common stock or any such other securities (regardless of whether any of these transactions are to be settled by the delivery of shares of common stock or such other securities, in cash or otherwise), in each case without the prior written consent of the representatives for a period of 180 days after the date of this prospectus (such period, the “restricted period”), other than the shares of our common stock to be sold in this offering.
SEC lock-up paragraph; source 2000552:2001889; SHA256 16054ac746afd4d76ce8469ab544ddfb3934a373058b267aaa0a1e8e84bd8950 ↗All shares of common stock expected to be sold in this offering will be freely tradable without restriction or further registration under the Securities Act of 1933, as amended (the “Securities Act”), unless held by our “affiliates” as defined in Rule 144 under the Securities Act. The resale of the remaining 64,301,057 shares, or 72.0% of our outstanding shares of common stock following this offering, is currently prohibited or otherwise restricted, subject to certain limited exceptions, as a result of securities law provisions, market standoff agreements entered into by certain of our stockholders with us or lock-up agreements entered into by our directors, officers and substantially all of our stockholders with the underwriters in connection with this offering under which they have agreed or will agree, subject to specific exceptions described in the section of this prospectus titled “Underwriting,” not to sell any of our stock for 180 days following the date of this prospectus. We refer to such period as the lock-up period. We and certain of the underwriters may release certain stockholders from the market standoff agreements or lock-up agreements prior to the end of the lock-up period. Subject to applicable securities law restrictions, these shares will be able to be sold in the public market beginning on the 181st day after the date of this prospectus. Shares issued upon the exercise of stock options outstanding under our equity incentive plans or pursuant to future awards granted under those plans will become available for sale in the public market to the extent permitted by the provisions of applicable vesting schedules, market stand-off agreements and/or lock-up agreements, as well as Rules 144 and 701 under the Securities Act. For more information, see the section titled “Shares Eligible for Future Sale” included elsewhere in this prospectus.
SEC lock-up paragraph; source 738245:740515; SHA256 dd1b4e091f6f3f2e67f8eb1408e38ccca4066021e97f18da36061b41c5c9301c ↗Source lock-up conditions
Literal day restriction; source duration bound ≥; after date of this prospectus; full conditions and exceptions remain in the source paragraph
| Measure | Reported value |
|---|---|
| We, all of our directors and executive officers, and the holders of substantially all of our capital stock and securities convertible into or exchangeable for our capital stock, representing 64,301,057 shares of our common stock, | ≥180 days |
Source and calculation
We, all of our directors and executive officers, and the holders of substantially all of our capital stock and securities convertible into or exchangeable for our capital stock, representing 64,301,057 shares of our common stock, have entered into lock-up agreements with the underwriters and/or are subject to market standoff agreements or other agreements with us, which prevents them from selling any of our common stock or any securities convertible into or exercisable or exchangeable for common stock for a period of not less than 180 days from the date of this prospectus without the prior written consent of J.P. Morgan Securities LLC, Jefferies LLC, Leerink Partners LLC and TD Securities (USA) LLC, subject to certain exceptions. See the section titled “Underwriting” appearing elsewhere in this prospectus for more information.
SEC lock-up paragraph; source 1953847:1954834; SHA256 6ef4b651bbc2bb348d17cab6a7411e3bc0e257a935c667381fca5173ee0efd3e ↗Conditional lock-up timeline
Conditional lock-up timeline
Eligibility is not a sale. Release conditions, holder groups and exceptions remain separate.
date of this prospectus
- WeWe have agreed that we will not (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, or submit to, or file with, the Securities and Exchange Commission a registration statement under the Securities Act relating to, any shares of our common stock or securities convertible into or exercisable or exchangeable for any shares of our common stock, or publicly disclose the intention to make any offer, sale, pledge, loan, disposition or filing, or (ii) enter into any swap or other arrangement that transfers all or a portion of the economic consequences associated with the ownership of any shares of common stock or any such other securities (regardless of whether any of these transactions are to be settled by the delivery of shares of common stock or such other securities, in cash or otherwise), in each case without the prior written consent of the representatives for a period of 180 days after the date of this prospectus (such period, the “restricted period”), other than the shares of our common stock to be sold in this offering.
- our stockholders with us or lock-up agreements entered into by our directors, officers and substantially all of our stockholders with the underwriters in connection with this offering under which theyAll shares of common stock expected to be sold in this offering will be freely tradable without restriction or further registration under the Securities Act of 1933, as amended (the “Securities Act”), unless held by our “affiliates” as defined in Rule 144 under the Securities Act. The resale of the remaining 64,301,057 shares, or 72.0% of our outstanding shares of common stock following this offering, is currently prohibited or otherwise restricted, subject to certain limited exceptions, as a result of securities law provisions, market standoff agreements entered into by certain of our stockholders with us or lock-up agreements entered into by our directors, officers and substantially all of our stockholders with the underwriters in connection with this offering under which they have agreed or will agree, subject to specific exceptions described in the section of this prospectus titled “Underwriting,” not to sell any of our stock for 180 days following the date of this prospectus. We refer to such period as the lock-up period. We and certain of the underwriters may release certain stockholders from the market standoff agreements or lock-up agreements prior to the end of the lock-up period. Subject to applicable securities law restrictions, these shares will be able to be sold in the public market beginning on the 181st day after the date of this prospectus. Shares issued upon the exercise of stock options outstanding under our equity incentive plans or pursuant to future awards granted under those plans will become available for sale in the public market to the extent permitted by the provisions of applicable vesting schedules, market stand-off agreements and/or lock-up agreements, as well as Rules 144 and 701 under the Securities Act. For more information, see the section titled “Shares Eligible for Future Sale” included elsewhere in this prospectus.
| Holder / event | Term / date | Conditions |
|---|---|---|
| We | 180 days | We have agreed that we will not (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, or submit to, or file with, the Securities and Exchange Commission a registration statement under the Securities Act relating to, any shares of our common stock or securities convertible into or exercisable or exchangeable for any shares of our common stock, or publicly disclose the intention to make any offer, sale, pledge, loan, disposition or filing, or (ii) enter into any swap or other arrangement that transfers all or a portion of the economic consequences associated with the ownership of any shares of common stock or any such other securities (regardless of whether any of these transactions are to be settled by the delivery of shares of common stock or such other securities, in cash or otherwise), in each case without the prior written consent of the representatives for a period of 180 days after the date of this prospectus (such period, the “restricted period”), other than the shares of our common stock to be sold in this offering. |
| our stockholders with us or lock-up agreements entered into by our directors, officers and substantially all of our stockholders with the underwriters in connection with this offering under which they | 180 days | All shares of common stock expected to be sold in this offering will be freely tradable without restriction or further registration under the Securities Act of 1933, as amended (the “Securities Act”), unless held by our “affiliates” as defined in Rule 144 under the Securities Act. The resale of the remaining 64,301,057 shares, or 72.0% of our outstanding shares of common stock following this offering, is currently prohibited or otherwise restricted, subject to certain limited exceptions, as a result of securities law provisions, market standoff agreements entered into by certain of our stockholders with us or lock-up agreements entered into by our directors, officers and substantially all of our stockholders with the underwriters in connection with this offering under which they have agreed or will agree, subject to specific exceptions described in the section of this prospectus titled “Underwriting,” not to sell any of our stock for 180 days following the date of this prospectus. We refer to such period as the lock-up period. We and certain of the underwriters may release certain stockholders from the market standoff agreements or lock-up agreements prior to the end of the lock-up period. Subject to applicable securities law restrictions, these shares will be able to be sold in the public market beginning on the 181st day after the date of this prospectus. Shares issued upon the exercise of stock options outstanding under our equity incentive plans or pursuant to future awards granted under those plans will become available for sale in the public market to the extent permitted by the provisions of applicable vesting schedules, market stand-off agreements and/or lock-up agreements, as well as Rules 144 and 701 under the Securities Act. For more information, see the section titled “Shares Eligible for Future Sale” included elsewhere in this prospectus. |
Basis and evidence
We have agreed that we will not (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, or submit to, or file with, the Securities and Exchange Commission a registration statement under the Securities Act relating to, any shares of our common stock or securities convertible into or exercisable or exchangeable for any shares of our common stock, or publicly disclose the intention to make any offer, sale, pledge, loan, disposition or filing, or (ii) enter into any swap or other arrangement that transfers all or a portion of the economic consequences associated with the ownership of any shares of common stock or any such other securities (regardless of whether any of these transactions are to be settled by the delivery of shares of common stock or such other securities, in cash or otherwise), in each case without the prior written consent of the representatives for a period of 180 days after the date of this prospectus (such period, the “restricted period”), other than the shares of our common stock to be sold in this offering.
SEC lock-up paragraph; source 2000552:2001889; SHA256 16054ac746afd4d76ce8469ab544ddfb3934a373058b267aaa0a1e8e84bd8950 ↗All shares of common stock expected to be sold in this offering will be freely tradable without restriction or further registration under the Securities Act of 1933, as amended (the “Securities Act”), unless held by our “affiliates” as defined in Rule 144 under the Securities Act. The resale of the remaining 64,301,057 shares, or 72.0% of our outstanding shares of common stock following this offering, is currently prohibited or otherwise restricted, subject to certain limited exceptions, as a result of securities law provisions, market standoff agreements entered into by certain of our stockholders with us or lock-up agreements entered into by our directors, officers and substantially all of our stockholders with the underwriters in connection with this offering under which they have agreed or will agree, subject to specific exceptions described in the section of this prospectus titled “Underwriting,” not to sell any of our stock for 180 days following the date of this prospectus. We refer to such period as the lock-up period. We and certain of the underwriters may release certain stockholders from the market standoff agreements or lock-up agreements prior to the end of the lock-up period. Subject to applicable securities law restrictions, these shares will be able to be sold in the public market beginning on the 181st day after the date of this prospectus. Shares issued upon the exercise of stock options outstanding under our equity incentive plans or pursuant to future awards granted under those plans will become available for sale in the public market to the extent permitted by the provisions of applicable vesting schedules, market stand-off agreements and/or lock-up agreements, as well as Rules 144 and 701 under the Securities Act. For more information, see the section titled “Shares Eligible for Future Sale” included elsewhere in this prospectus.
SEC lock-up paragraph; source 738245:740515; SHA256 dd1b4e091f6f3f2e67f8eb1408e38ccca4066021e97f18da36061b41c5c9301c ↗Financial quality
Bars compare absolute amounts within each measure. Each measure has its own scale.
Net income / (loss)
$ · Annual values as reported · ConsolidatedOperating cash flow
$ · Annual values as reported · Consolidated| Calculation | FY2024 | FY2025 |
|---|---|---|
| Net income / (loss)Consolidated | ($88,658) | ($191,941) |
| Operating cash flowConsolidated | ($18,825) | ($151,056) |
| Calculation | Reported value |
|---|---|
| Cash and cash equivalents2025-12-31 · Consolidated | $108,989 |
| Cash and cash equivalents2024-12-31 · Consolidated | $49,402 |
| Current assets2025-12-31 · Consolidated | $345,353 |
| Current assets2024-12-31 · Consolidated | $50,318 |
| Total assets2025-12-31 · Consolidated | $390,942 |
| Total assets2024-12-31 · Consolidated | $63,526 |
| Current liabilities2025-12-31 · Consolidated | $37,536 |
| Current liabilities2024-12-31 · Consolidated | $8,285 |
| Total liabilities2025-12-31 · Consolidated | $55,127 |
| Total liabilities2024-12-31 · Consolidated | $26,698 |
| Total equity / (deficit)2025-12-31 · Consolidated | ($250,335) |
| Total equity / (deficit)2024-12-31 · Consolidated | ($83,194) |
| General and administrative expensesFY2025 · Consolidated | $48,750 |
| General and administrative expensesFY2024 · Consolidated | $12,362 |
| Cash and cash equivalents2026-03-31 · Consolidated · Unaudited | $81,548 |
| Cash and cash equivalents2025-12-31 · Consolidated · Unaudited | $108,989 |
| Current assets2026-03-31 · Consolidated · Unaudited | $298,134 |
| Current assets2025-12-31 · Consolidated · Unaudited | $345,353 |
| Total assets2026-03-31 · Consolidated · Unaudited | $348,190 |
| Total assets2025-12-31 · Consolidated · Unaudited | $390,942 |
| Current liabilities2026-03-31 · Consolidated · Unaudited | $31,665 |
| Current liabilities2025-12-31 · Consolidated · Unaudited | $37,536 |
| Total liabilities2026-03-31 · Consolidated · Unaudited | $51,270 |
| Total liabilities2025-12-31 · Consolidated · Unaudited | $55,127 |
| Total equity / (deficit)2026-03-31 · Consolidated · Unaudited | ($300,626) |
| Total equity / (deficit)2025-12-31 · Consolidated · Unaudited | ($250,335) |
| General and administrative expenses3M ended 2026-03-31 · Consolidated · Unaudited | $13,643 |
| General and administrative expenses3M ended 2025-03-31 · Consolidated · Unaudited | $7,304 |
| Net income / (loss)3M ended 2026-03-31 · Consolidated · Unaudited | ($56,071) |
| Net income / (loss)3M ended 2025-03-31 · Consolidated · Unaudited | ($18,019) |
| Operating cash flow3M ended 2026-03-31 · Consolidated · Unaudited | ($56,776) |
| Operating cash flow3M ended 2025-03-31 · Consolidated · Unaudited | ($21,400) |
Basis and evidence
Financial quality and runway
Financial quality and runway
Latest March 2026 data show $287.1 million cash/investments but a $56.1 million quarterly loss and explicit pre-IPO going-concern doubt.
EvidenceFinancial review 1First-quarter 2026 R&D was $45.067 million and total operating expenses $58.710 million, versus $18.774 million and $26.078 million a year earlier.
+
First-quarter 2026 R&D was $45.067 million and total operating expenses $58.710 million, versus $18.774 million and $26.078 million a year earlier.
EvidenceFinancial review 2First-quarter 2026 net loss was $56.071 million versus $18.019 million in first-quarter 2025; full-year 2025 loss was $191.941 million.
+
First-quarter 2026 net loss was $56.071 million versus $18.019 million in first-quarter 2025; full-year 2025 loss was $191.941 million.
EvidenceFinancial review 3At March 31, 2026, cash was $81.548 million, short-term investments $205.560 million, total assets $348.190 million and liabilities $51.270 million.
+
At March 31, 2026, cash was $81.548 million, short-term investments $205.560 million, total assets $348.190 million and liabilities $51.270 million.
EvidenceFinancial review 4Management concluded pre-IPO resources were insufficient for at least 12 months, but estimates IPO proceeds and existing funds support operations into 2028.
+
Management concluded pre-IPO resources were insufficient for at least 12 months, but estimates IPO proceeds and existing funds support operations into 2028.
Baseline filing — comparison pending
No source-comparable material changes identified in this report.
No source-comparable material changes identified in this report.
424B40001193125-26-276096 ↗
Loading filing history…